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Rapid changes in World demographics have resulted in an “epidemic” of elderly people living with complex health issues affecting quality of life and requiring multiple drug therapy. Worldwide, it is expected that by 2050 approximately 400 million people will be ≥ 80 years of age (1). In a review of 39 studies in primary care (70,057,611 patients), 95.1% of people aged ≥65 years have co-morbidities (2) and in a Scottish database of more than 1.2 million people, 76.5% of those aged ≥75 years had multiple co-morbidities (3). Compared to younger adults, treatment in the elderly is complicated by age-related changes in body composition, structure and function of the cardiovascular system and other organs, changes in homeostatic mechanisms and coexisting comorbidities that also affect drug pharmacokinetics (i.e., absorption, distribution, metabolism, and excretion) and pharmacodynamics (i.e. the relationship between drug effect and drug concentration at the site of action)  often require changes in drug dosing (4-6). Changes in pharmacokinetics associated with aging are summarized in Table 1. Aging can increase the exposure and prolong the half-life of cardiovascular drugs, so dose adjustments are often required in the elderly. Gastric pH, gastric emptying rate, gastrointestinal motility and splachnic blood flow are decreased in the elderly, potentially affecting drug absorption. Aging produces changes in body composition that can affect the volume of distribution and the half-life of lipophilic drugs and other agents. The biotransformation of some cardiovascular drugs that occurs mainly in the liver can be also affected in the elderly, resulting in an increase in plasma levels and half-lives of some cardiovascular drugs. Aging is also associated with a reduction in kidney size, renal blood flow, glomerular filtration rate and tubular secretion, which can, in turn, reduce the elimination rate of renally-cleared drugs even in the absence of overt renal disease.
Age-related changes in end-organ responsiveness can also affect the pharmacodynamics of cardiovascular drugs. Thus, elderly people are more likely than younger individuals to develop orthostatic hypotension (and falls) with the use of vasodilator or antihypertensive agents, bradycardia, atrioventricular conduction block and tachyarrhythmias in response to antiarrhythmic drugs, hypovolemia in response to diuretics and bleeding complications with the use of antithrombotic agents.
Polypharmacy
Polypharmacy is a growing problem in the elderly with 50% of adults using ≥5 medications and nearly 20% taking ≥10 medications, which increases the risk of adverse effects and drug-drug interactions, decreases medical adherence and . Prescription of a potentially inappropriate medication (PIM) is particularly frequent in the elderly with multiple prescribers or hospitalizations and is associated with increased frailty. Underuse of potentially beneficial medications is also of concern among frail older people and some patients do not receive potentially beneficial medications, i.e., anticoagulants for atrial fibrillation, antidepressants or acetylcholinesterase inhibitors for dementia. The use of over the counter (OTC) medications and herbal medicines is common among older people. 
Adherence
Poor medication adherence contributes to suboptimal clinical benefits and severely compromises patient outcomes. In the elderly, barriers to compliance include forgetfulness and confusion, decreased dexterity and mobility or sensory abilities, reduced affordability or intolerable adverse events. Approximately 50% of patients do not take medications as prescribed and half of all filled prescriptions were incorrectly taken, but patients are often reluctant to admit to non-adherence. 
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